Compile Data Set for Download or QSAR
maximum 50k data
Found 262 with Last Name = 'berman' and Initial = 'c'
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342149(1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  0.100nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342128(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  0.300nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342122(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  0.400nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342117(N-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  0.600nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342121(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342122(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342119(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342120(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  1.10nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342115(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  1.40nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025450(CHEMBL1790294 | Sodium; 1,4a,6a-trimethyl-2-oxo-he...)
Affinity DataKi:  1.70nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342151(N-(4-(3-((2-(tert-butyl)-4-(m-tolyl)thiazol-5-yl)m...)
Affinity DataKi:  2.30nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342130(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  2.35nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342129(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  4.70nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50213061(CHEMBL2298601)
Affinity DataKi:  5nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342121(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  5.20nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342147(1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  5.90nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50367296(CHEMBL1790284)
Affinity DataKi:  6nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342150(N-(4-(3-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol...)
Affinity DataKi:  6.60nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342118(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  7.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342144(N-((5-(3-chlorophenyl)-2-(tertbutyl)thiazol-5-yl)m...)
Affinity DataKi:  9.10nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342148(1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  12.3nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50226049(CHEMBL3349139)
Affinity DataKi:  13nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342127(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  13.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342138(N-(4-(3-((2-(tert-butyl)-4-(3-fluorophenyl)thiazol...)
Affinity DataKi:  17.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342132(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  19.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025400(1'-ethyl-4a',6a'-dimethylspiro[tetrahydrofuran-2,7...)
Affinity DataKi:  24nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342135(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  24.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342140(1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  27.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342116(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  28.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50216166(CHEMBL3349181)
Affinity DataKi:  29nMAssay Description:Apparent inhibitory constant value for rat prostatic steroid 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342142(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  29.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342143(N-((5-(3-chlorophenyl)-2-(tertbutyl)oxazol-4-yl)me...)
Affinity DataKi:  29.9nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342145(1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...)
Affinity DataKi:  33.3nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342146(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  35nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342122(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  41.9nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342139(1-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-5-yl)m...)
Affinity DataKi:  43.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342133(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...)
Affinity DataKi:  48.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342137(N-(4-(3-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-...)
Affinity DataKi:  52.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342134(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  60.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342131(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  62.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342136(1-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-5-yl)m...)
Affinity DataKi:  78.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342121(N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  96.7nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt

US Patent
LigandPNGBDBM342141(1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...)
Affinity DataKi:  103nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50225982(CHEMBL3349117)
Affinity DataKi:  133nMAssay Description:In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025359(1,4a,6a-Trimethyl-2-oxo-hexadecahydro-indeno[5,4-f...)
Affinity DataKi:  165nMAssay Description:Apparent inhibitory constant value for rat prostatic 5-alpha reductase was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025367(4a,6a-Dimethyl-2-oxo-hexadecahydro-indeno[5,4-f]qu...)
Affinity DataIC50:  0.130nMAssay Description:In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50225985(CHEMBL3349105)
Affinity DataIC50:  0.210nMAssay Description:In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025454(1,4,4a,6a-Tetramethyl-2-oxo-hexadecahydro-indeno[5...)
Affinity DataIC50:  0.560nMAssay Description:In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target3-oxo-5-alpha-steroid 4-dehydrogenase 1/2(Rattus norvegicus)
TBA

Curated by ChEMBL
LigandPNGBDBM50025341(4a,6a-Dimethyl-7-(3-methyl-butyryl)-hexadecahydro-...)
Affinity DataIC50:  1.20nMAssay Description:In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAndrogen receptor(Rattus norvegicus (Rat))
TBA

Curated by ChEMBL
LigandPNGBDBM50025425(17-Hydroxy-10,13-dimethyl-4,5,6,7,8,9,10,11,12,13,...)
Affinity DataIC50:  1.5nMAssay Description:In vitro antagonist activity against rat prostatic androgen receptor (AR)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 262 total ) | Next | Last >>
Jump to: